WS
NVCR icon

Wedbush Securities’s NovoCure NVCR Stock Holding History

Wedbush Securities’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,805
Closed -$241K – 1012
2019
Q2 		$241K Buy
+3,805
New +$193K 0.02% 736
2017
Q3 		– Sell
-31,340
Closed -$542K – 861
2017
Q2 		$542K Sell
31,340
-15,749
-33% -$203K 0.07% 362
2017
Q1 		$381K Buy
+47,089
New +$340K 0.05% 439

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wedbush Securities's NVCR Position: Q3 2019 in Review

Wedbush Securities sold out of NovoCure (NVCR) in Q3 2019, closing a stake of 3,805 shares — an estimated $241K sold.

Wedbush Securities first reported a position in NVCR in Q1 2017 and held it in 3 quarters. The position peaked at $542K in Q2 2017. 240 funds tracked by Wall St. Rank hold NVCR as of Q3 2019.

  • Wedbush Securities reported no remaining NovoCure position as of Q3 2019 after selling out during the quarter.
  • Wedbush Securities sold 3,805 NovoCure shares in Q3 2019, an estimated $241K.
  • Wedbush Securities first reported a position in NovoCure in Q1 2017 and held it in 3 quarters.
  • Wedbush Securities's NovoCure position peaked at $542K in Q2 2017.
  • 240 funds tracked by Wall St. Rank held NovoCure as of Q3 2019.

Based on Wedbush Securities's 13F filing for Q3 2019, filed 17 Oct 2019.